Whitehawk Therapeutics, Inc. Common Stock WHWK Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0-100% | $7.15M-50.3% | $14.38M-33.4% | $21.6M-22.2% | $27.78M+6.9% | ||
| $0-100% | $760K-51.0% | $1.55M-34.2% | $2.35M-24.8% | $3.13M+3.6% | ||
| $0-100% | $6.39M-50.2% | $12.83M-33.3% | $19.24M-21.9% | $24.64M+7.3% | ||
| $99.41M+9.3% | $90.96M+5.4% | $86.29M+5.3% | $81.94M+77.3% | $46.23M-9.4% | ||
| $23.3M-21.9% | $29.82M-14.8% | $35.01M-5.4% | $36.99M-5.0% | $38.94M+6.0% | ||
| $122.7M+1.0% | $121.55M-1.1% | $122.85M-0.9% | $123.93M+36.3% | $90.94M-2.7% | ||
| -$122.7M-7.3% | -$114.4M-5.5% | -$108.46M-6.0% | -$102.33M-62.0% | -$63.16M+6.4% | ||
| $6.77M+8.6% | $6.23M+17.7% | $5.3M+21.7% | $4.35M+26.7% | $3.43M-12.5% | ||
| $6.9M-92.6% | $93.8M+1.0% | $92.84M+1.0% | $91.91M+1.2% | $90.78M+2,310% | ||
| -$177K-100% | $87.27M0.0% | $87.27M-0.2% | $87.44M0.0% | $87.44M— | ||
| —— | —— | —— | —— | $25.25M+140% | ||
| —— | —— | —— | —— | $0— | ||
| -$115.81M-462% | -$20.6M-31.9% | -$15.62M-49.9% | -$10.42M-138% | $27.61M+143% | ||
| -$1.71-489% | $0.44+238% | $0.13+286% | -$0.07-147% | $0.15+106% | ||
| -$1.71-480% | $0.45+221% | $0.14+333% | -$0.06-137% | $0.16+107% | ||
| 269.4M+12.2% | 240.1M+17.0% | 205.3M+25.9% | 163.1M+34.8% | 121M+12.0% | ||
| 269.4M+12.3% | 239.8M+17.0% | 205M+25.9% | 162.8M+34.9% | 120.7M+11.7% | ||
| -$115.82M-465% | -$20.49M-32.1% | -$15.52M-49.5% | -$10.38M-138% | $27.62M+143% | ||
| -$177K-100% | $87.27M0.0% | $87.27M-0.2% | $87.44M0.0% | $87.44M— | ||
| —— | —— | $100K+178% | $36K+300% | $9K+182% | ||
| $6.9M-92.6% | $93.8M+1.0% | $92.84M+1.0% | $91.91M+1.2% | $90.78M+2,310% | ||
| $0-100% | $7.15M-50.3% | $14.38M-33.4% | $21.6M-22.2% | $27.78M+6.9% | ||
| -$122.7M-7.3% | -$114.4M-5.5% | -$108.46M-6.0% | -$102.33M-62.0% | -$63.16M+6.4% | ||
| -$122.64M-7.3% | -$114.32M-5.5% | -$108.36M-6.0% | -$102.2M-62.2% | -$63M+6.3% | ||
| -$122.64M-7.3% | -$114.32M-5.5% | -$108.36M-6.0% | -$102.2M-62.2% | -$63M+6.3% | ||
| -$122.7M-7.3% | -$114.4M-5.5% | -$108.46M-6.0% | -$102.33M-62.0% | -$63.16M+6.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Whitehawk Therapeutics, Inc. Common Stock profitable?
- Whitehawk Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $115.8M over the trailing twelve months, a -288.3% net margin.
- What are Whitehawk Therapeutics, Inc. Common Stock's profit margins?
- Gross margin is 89.4% and operating margin is -1601.1%, with a -288.3% net margin.
- What is Whitehawk Therapeutics, Inc. Common Stock's earnings per share?
- Whitehawk Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-1.71.
- Where does Whitehawk Therapeutics, Inc. Common Stock's income statement data come from?
- Every line is extracted from Whitehawk Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.